Isolation and culture of gut bacteria enable testing for microbial roles in disease and 31 may also lead to novel therapeutics. However, the diversity of human gut microbial 32 communities (microbiota) impedes comprehensive experimental studies of individual 33 bacterial taxa. Here, we combine advances in droplet microfluidics and high-throughput 34 DNA sequencing to develop a platform for isolating and assaying microbiota members 35 in picoliter droplets (MicDrop). MicDrop can be used to create millions of distinct 36 bacterial colonies in a single experiment while using off-the-shelf parts compact enough 37 to fit in an anaerobic chamber. In proof-of-concept experiments, we used the platform to 38 
Introduction 46
Bacterial culture was among the first techniques used to study human gut microbiota 1 . 47
Bacterial isolation efforts beginning in the early 1900s identified key enteric genera such 48
as Bacteroides, Bifidobacterium, and Bacillus 2 . Microbes isolated since then have 49 served as crucial reagents for experiments. Gut bacterial isolates allow testing causal 50 roles for specific microbes in animal models of metabolic and auto-immune disorders [3] [4] [5] . 51
Bacterial isolates can also be genetically modified and tested in vitro to identify 52 enzymatic machinery in processes like the fermentation of dietary fiber 6 , and cocktails of 53 cultured bacteria are being explored as therapeutics for C. difficile infections and 54 cancer [7] [8] [9] . 55
Yet a key challenge for current microbiota culturing efforts has been keeping 56 pace with increasing knowledge and interest in gut microbial diversity. Culture-57 independent methods based on high-throughput 16S rRNA sequencing have revealed 58 the average individual harbors hundreds of distinct enteric bacterial strains [10] [11] [12] [13] . 59
Moreover, unrelated individuals likely share no more than ~30% of bacterial strains 14 . 60
Prevailing culture techniques do not scale to the diversity of microbes spanning human 61 populations. Because most taxa are rare, exhaustive capture of bacterial species from 62 even a single stool sample requires laborious spotting of thousands of bacterial 63 colonies 15, 16 . To reduce the human effort needed for such experiments, state-of-the-art 64 culture assays leverage plate and liquid handling robots; but, even these automated 65 efforts tend to be limited to tens of strains 17, 18 . This limitation stems in part from the 66 physical constraints of typical plate-based culture methods, which grow bacteria in wells 67
ranging from centimeters to millimeters in diameter. Even relying on 96-and 384-well 68 plates, conventional large-scale culture efforts may require loading and handling dozens 69 of plates under anaerobic conditions 18 . 70
An alternative approach is to culture bacteria in small volumes (nano-to pico-71 liters) by separating microbes into microscale wells. Devices composed of thousands of 72 such wells have been used to culture both lab strains of bacteria and fungi 19 , as well as 73 isolate previously uncultured bacteria from the gut and soil 20, 21 . Even higher-throughput 74 experiments are possible by compartmentalizing microbes in droplets of media that are 75 tens to hundreds of microns in diameter and separated by immiscible oils and 76 engineered surfactants 22, 23 . Because droplets are not limited by the need to 77 microfabricate physical wells or channels, millions of distinct culture volumes can be 78 created on the order of minutes. Droplet techniques have so far been used to isolate 79 uncultured microbes from seawater and soil communities 20,24,25 , assess microbial cross-80 feeding 26 , track population dynamics of individual bacteria 27 , and examine antibiotic 81 sensitivity and commensal-pathogen interactions of human gut and oral microbiota 28, 29 . 82
Still, existing droplet microfluidic approaches for assaying bacteria have required 83 combining complex emulsion techniques (water-oil-water) with flow cytometers or 84 custom on-chip droplet sorting devices. These protocol requirements limit the 85 accessibility of droplet technologies for bacterial assays and in their present form 86 require equipment that does not fit into typical anaerobic chambers, which are needed 87 to culture human gut bacteria 30 . 88
Here, we developed a platform to isolate and culture bacteria from human gut 89 microbiota in droplets (MicDrop) using accessible techniques and equipment. A key 90 challenge our method addresses is how to measure the growth of isolates within distinct 91 microfluidic droplets. To accomplish this, we rely on 16S rRNA as intrinsic DNA 92 barcodes that are shared between droplets carrying the same bacterial taxa, which we 93 refer to here as a sequence variant or SV 31 . This approach in turn allows us to measure 94 isolate growth in droplets without the need for double-emulsion techniques or droplet 95 sorting. Instead, we combine single-emulsion (water-in-oil) microfluidic droplet protocols 96 with molecular techniques (qPCR and 16S rRNA sequencing). These simplified 97 protocols allow us to employ off-the-shelf microfluidic pumps and chips, which are 98 compact enough to fit within typical anaerobic chambers. Using MicDrop, we 99 characterized dietary polysaccharide metabolism among hundreds of gut bacteria from 100 nine individuals. We then employed MicDrop to generate growth curves for dozens of 101 distinct SVs in a single experiment, which we in turn used to investigate long-term 102 microbiota dynamics of an artificial human gut. Together, these findings showcase the 103 potential for microfluidic droplet techniques to characterize the growth and function of 104 individual bacterial strains from complex gut microbial communities in high-throughput. 105 106 107
Results

108
MicDrop: a platform for culturing human gut microbiota in droplets 109
To isolate and culture individual gut bacteria from human gut microbiota, we 110 merged concepts from prior microfluidic droplet protocols with high-throughput DNA 111 sequencing ( Fig. 1 ; Experimental Procedures). Our protocol first randomly encapsulates 112 individual bacterial cells from gut microbiota into picoliter-sized droplets (Fig. 1A) . Gut 113 microbiota samples are diluted before encapsulation using the Poisson distribution at a 114 loading concentration that optimizes the number of droplets loaded with cells (~10-26%) 115 against the number of droplets loaded with more than one microbe (~95-86% of loaded 116 droplets contain single cells) ( Supplementary Fig. 1 ) 32 . Since many gut bacteria are 117 obligate anaerobes, encapsulation takes place in an anaerobic chamber and droplets 118 are subsequently incubated under anaerobic conditions ( Supplementary Fig. 2 ). To 119 track SV growth, we can avoid having to identify and sort bacteria by assuming that 120 droplets are either empty or loaded with clonal isolates whose progeny share the same 121 16S ribosomal rRNA (rRNA) sequence, meaning genomic material accumulating across 122 all droplets reflects the growth of SVs grown in isolation (Fig. 1A-D) . We therefore track 123 isolate growth in droplets at a given time point using bulk bacterial DNA extraction 124 without droplet sorting, followed by DNA sequencing and total quantification (qPCR) of 125 16S rRNA. The product of relative SV levels from 16S rRNA sequencing and total 16S 126 rRNA levels yields an estimate of the absolute levels of each SV across all droplets at 127 the time of sampling. To explore the feasibility of the MicDrop platform, we initially examined bacterial 140 replication and isolation in droplets, as well as the use of DNA sequencing to track 141 bacterial levels. We found aerobic monocultures of fluorescent Escherichia coli 142 replicated in droplets in a qualitative manner that resembled growth on conventional 143
Petri dishes (Supplementary Fig. 3 bacteria could be studied in droplets for at least 5 days ( Supplementary Fig. 4 ). Next, 145 microscopy showed droplets could be used to segregate clonal isolate populations with 146 distinct morphology and motility out of mixed microbial communities (Supplementary 147 Fig. 5 ). Human fecal microbiota isolated and cultured in droplets exhibited 2.6 times 148 more diversity than when grown in mixed conditions ( Supplementary Fig. 6 ), which is 149 consistent with the hypothesis that droplet isolation enables slow-growing microbes to 150 be sheltered from competition with fast-growing bacteria 20 . Last, we found DNA-based 151 techniques could be used to track bacterial levels in droplets. Quantitative growth 152 measurements using qPCR of the 16S rRNA gene sampled every two hours from liquid 153 cultures were also similar to E. coli grown on plates (ρ=0.95, p=8.7e-9; Spearman 154 correlation; Supplementary Fig. 7 ). Next, using DNA sequencing, we analyzed a mixture 155 of 10 bacterial strains that were isolated using MicDrop and grown under varying 156 antibiotic conditions for 24 hours. We found that resulting bacterial DNA levels in 157 droplets corresponded to isolates' optical densities in reference well-plates 158 (accuracy=75%; Supplementary Fig. 8 (Fig. 2B) . We next tested how the MicDrop prebiotic assay 177 performed using artificial microbial communities assembled from seven human gut 178 isolates (Fig. 2E) . Using 96-well plate experiments as our reference ( Fig. 2C & 2D , 179 Supplementary Fig. 9 ), we found the sensitivity, specificity, and false discovery rate of 180 the MicDrop prebiotic assay to be 80%, 93%, and 9%, respectively (Supplementary 181 
Identifying primary degraders from human guts across multiple prebiotics 202
We next applied the MicDrop prebiotic assay to microbiota from nine healthy 203 human stool donors. We assayed growth on three consumer-grade prebiotics (inulin, 204 galacto-oligosaccharides (GOS), and dextrin) and a lab-grade prebiotic (xylan). Out of 205 the 588 SVs detected across donor stool samples, MicDrop identified a total of 285 206 primary degraders that grew on at least one of the screened prebiotics (Fig. 3A) . 207
Prebiotic utilization patterns of primary degraders were similar to those of matched 208 bacterial strains in a reference database of microbial carbohydrate utilization 45, 46 . 209
Among the instances when matched bacteria were annotated as consuming a prebiotic 210 in the database, 86% were detected by MicDrop (p<0.001; permutation test). Still, we 211 did find that 52% of instances when MicDrop indicated a primary degrader to consume 212 a prebiotic were not reported for matched bacteria in the database (p=0.34; permutation 213 test), which may in part reflect incomplete enumeration of bacterial carbohydrate 214 utilization in the reference. 215
We next explored the hypothesis that differences in the presence or absence of 216 primary degraders could drive inter-individual variation in human prebiotic response. 217
Evidence arguing against this hypothesis included observing that multiple SVs capable 218 of growing on the tested prebiotics were present in all subjects (median: 12.5 ± 6.1); 219 Still, we also found evidence for inter-individual variation in primary degrader 226 composition and abundance. We observed differences in the richness of primary 227 degraders across subjects (p<0.001, Two-way ANOVA; Fig. 3B ). We also found subject 228 identity explained more variation (R 2 =0.30, PERMANOVA; Supplementary Table 3) High-throughput estimation of growth dynamics of human gut microbiota 246
In a second set of demonstration experiments, we used the MicDrop platform to 247 explore the dynamics of human gut microbiota in artificial gut systems. Such systems 248 have been used when in vivo microbiota research is challenging, including measuring 249 the effects of nutrition on the infant gut, systematic antibiotic testing, and investigating 250 chemotherapy-induced dysbioses 47, 48, 49 . Still, a recurring challenge of artificial gut 251 models has been their inability to completely reconstruct in vivo microbial communities. 252
After inoculation, these models often decrease in diversity within 24 hours [50] [51] [52] , and as 253 little as 15% of the starting community may ultimately remain after a week of culture 53 . A 254 potential explanation for part of this diversity loss is that bacteria are sensitive to media 255 conditions: studies using individual gut bacterial strains show growth can be affected by 256 even a single medium component 54 ; and, varying media used in artificial guts leads to 257 broad scale changes in microbial community structure 55, 56 . Still, the hypothesis that 258 individual gut microbes' suitability to media is associated with their long-term 259 persistence in artificial gut models has not been fully explored, likely due in part to the 260 challenges of isolating and assaying each component species in these communities. 261
To test the hypothesis that growth of individual microbial SVs in a particular 262 medium would correspond to SV persistence in an artificial gut setting, we used stool 263 from a healthy human donor to inoculate a continuous flow bioreactor system we have 264 used in past gut microbial ecology studies 57, 58 . The artificial gut was supplied with 265 modified Gifu Anaerobic Medium (mGAM) 59 , which features a variety of carbon and 266 nitrogen sources, as well as extra amino acids, vitamin K, and hemin. We chose mGAM 267 because it enables a wide growth of mammalian gut bacteria 54, 59 . Yet, despite this 268 choice of medium, microbiota dynamics in the artificial gut exhibited the same loss in 269 diversity observed in prior studies ( Supplementary Fig. 10 ) 50, 53 . At the end of two weeks 270 of culture, only 23% and 18% of inoculating bacteria genera and SVs, respectively, 271
were still detected in the artificial gut (Supplementary Table 4) . 272
A fresh stool sample from the same donor used to inoculate the artificial gut was 273 then assayed by the MicDrop platform. To additionally demonstrate the potential for 274
MicDrop to assess the kinetics of bacterial growth over time, we created replicate 275 droplet populations and destructively sampled them at hourly intervals for the first 24 276 hours, and daily for four subsequent days after inoculation. Among the resulting time 277 series, 94 SVs were detectable in droplets, meaning they appeared in >5 time points; 278 Table 1 , Supplementary Fig. 11 ). These SVs included representatives from the major 279 human gut bacterial phyla (the Actinobacteria, Bacteroidetes, Firmicutes, and 280 Proteobacteria) and represented 76% of the inoculum's SVs, a proportion approaching 281 prior culture efforts using mGAM medium 59 . Of the detectable SVs, we then measured 282 how many exhibited evidence for growth in droplets. We defined a cut-off for growth as 283 inferred doublings of at least 2.14 times (∆ ln(SV DNA abundance) ≥ 1.48) based on our 284
antibiotic-based control experiments ( Supplementary Fig. 8 ). A total of 34 SVs were 285 defined as growing (Fig. 4A) , which accounted for 25% of the inoculum's SVs. Of the 286 SVs with positive growth, 12 SVs were not detected by sequencing in the inoculum, 287 which suggests they could be laboratory contaminants. Still, these SVs resemble known 288 gut bacteria (Supplementary Table 5 ) and may alternatively represent rare microbes 289 that require culture to be detected, which is a previously reported phenomenon 60 . 290 according to total growth (curve asymptote height; indicated by ∆), which is denoted on 302 each sub-plot. Only SVs inferred to double at least 2.14 times were considering growing 303 and are shown (ln(∆ SV DNA abundance) ≥1.48; threshold determined using control 304 experiments in Supplementary Fig. 8 ). To ease viewing, curves are shifted vertically so 305 y-intercepts are at the origin. (B) Long-term abundance of SVs in an artificial gut 306 (grouped across days 7-14) grouped by whether SVs were identified by MicDrop as 307 growing (doubling ≥ 2.14 times) or non-growing doubling < 2.14 times) (Mann-Whitney 308 U, p < 0.02). (i.e. 1-5 days after inoculation), which is consistent with the notion that non-growing SVs 315 require several days to wash out of an artificial gut after inoculation. However, from day 316 7-14 of the artificial gut experiment, we observed elevated abundances among artificial 317 gut SVs that grew in the MicDrop platform (inferred doublings ≥ 2.14) relative to ones 318 that did not (SV doublings < 2.14) (p < 0.02, Mann-Whitney U test) (Fig. 4B ). This 319 difference in abundance increased over time in the artificial gut system (ρ = 0.80, p < 320 1e-4, Spearman correlation) (Fig. 4C) . Still, some SVs grew well in droplets, but did not 321 persist in the artificial gut (left-most points of upper bar in The ability of MicDrop to screen clonal populations could be particularly useful for 338 assays characterizing the behavior of isolates free from the effects of inter-species 339 interactions like competition or facilitation 17, 18 . 340
Yet, we acknowledge MicDrop still has some limitations. We rely on 16S rRNA as 341 a molecular barcode for droplets sharing the same bacterial SV, meaning that the 342 platform is sensitive to similar challenges due to inter-species rRNA copy number 343 limited this study to healthy subjects who could provide fecal samples at no risk to 609 themselves, had no acute enteric illness (e.g. diarrhea) and had not taken antibiotics in 610 the past month. Fresh stool samples were collected in a disposable commode specimen 611 container (Fisher Scientific, Hampton NH). Intact stool was moved within roughly 15 612 minutes of bowel movement into anaerobic conditions. The sample was prepared for 613 inoculation in an anaerobic chamber (Coy). A 5 g stool aliquot was weighed into a 7 oz 614 filtration bag (Nasco Whirl-Pak) and combined with 50 mL of mGAM media (Gifu 615
Anaerobic Medium, HiMedia, with the addition of 5 mg/L Vitamin K and 10 mg/L Hemin, 616 59 ) that was pre-reduced overnight in an anaerobic chamber. The mixture was 617 homogenized in a stomacher (Seward Stomacher 80) on normal speed for 1 minute 618 under atmospheric conditions to make a total of 100 mL of inoculum. The supernatant 619 was decanted into beakers and loaded into syringes for inoculation into the artificial gut 620 or filtered through a 50 µm filter (Celltrics) and diluted and loaded into droplets. 621 622 Droplet DNA extraction, PCR amplification, and DNA sequencing 623
To extract DNA from droplets, excess oil was removed by pipetting and water-in-624 oil emulsions were broken by adding an equal amount of 1H,1H,2H,2H-Perfluoro-1-625 octanol (PFO, VWR) and briefly vortexed. Then, the samples were briefly centrifuged 626 (<200 g) to separate the aqueous and oil phases by density. The aqueous solution was 627 transferred to a new tube, and DNA was extracted using a kit (Qiagen #12224). DNA 628 was extracted from artificial gut and stool samples using a 96-well PowerSoil kit (Qiagen 629 #12888). For all samples, the V4 region of the 16S rRNA gene was barcoded and 630 amplified from extracted DNA using with custom barcoded primers, using published 631 protocols 68,69 . 16S rRNA amplicon sequencing was performed on an Illumina MiniSeq 632 with paired-end 150 bp reads. We chose to only analyze samples with more than 5,000 633 reads to remove outlying samples that may have been subject to library preparation or 634 sequencing artifacts. The 16S rRNA nucleotide sequences generated in this study will 635 be made available at the European Nucleotide Archive under study accession number 636 TBD. Total bacterial abundances from droplet cultures were estimated by qPCR for 637 bacterial 16S rRNA using the same primers used in the DNA sequencing protocol. 638
Amplification during the qPCR process was measured with a Real-Time PCR system 639 (CFX96 Real-Time System, BioRad) using E. coli DNA at a known cell concentration as 640 a reference. 641
642
Identifying Sequence Variants and Taxonomy assignment 643 DADA2 was used to identify SVs 31 . Custom scripts were used to prepare data for 644 denoising with DADA2 as previously described 57 . Reads were then demultiplexed using 645 scripts in Qiime v1.9 70 . SVs were inferred by DADA2 using error profiles learned from a 646 random subset of 40 samples from each sequencing run. Bimeras were removed using 647 the function removeBimeraDenovo with tableMethod set to "consensus". Taxonomy was 648 assigned to sequence variants using a Naïve Bayes classifier 71 trained using version 649 123 of the SILVA database 72 . For growth dynamics of the human gut microbiota and 650 microbiota dynamics in the artificial gut, only forward sequencing reads were analyzed. 651 Downstream analysis on sequence variant tables was performed using R (ver. 3.4.2) 652 and Python (ver. 2.7.6). PERMANOVA was run in R using adonis in the vegan package 653 (ver. 2.5-2). 654
655
Growth dynamics of human gut microbiota 656 the inoculum. We fit curves using the module scipy.optimize.least_squares with the 680 robust loss function "soft_l1". Parameter bounds were also used to minimize the 681 optimization search space. We set lower bounds of A=0, λ=-50, µ=0, A0=0; and, upper 682 bounds of A=15, λ=12, µ=2.6, A0=15. We selected bounds by considering both 683 biological feasibility and parameter sensitivity analyses (Supplementary Fig. 12 ). Our 684 upper bound for growth rate (µ=2.6) represented a doubling time of 15 minutes, which 685 we based on the fastest growth rates observed in an anaerobic bacterium 74 . The upper 686 bounds on A and A0 were set to the maximum amount of DNA measured across 687 replicate MicDrop samples from the human fecal inoculum. The upper bound on λ, 688 which represents the lag time until exponential growth 75 was set at 12. Lower bounds of 689 0 for A, A0, and µ reflect our choice not to model negative growth. A lower bound for λ 690 was selected by sensitivity analysis (Supplementary Fig. 12 ), which revealed that a 691 bound of zero led to fitted λ values regularly collapsing to our boundary limits. We also 692 found that fitted curves were sensitive to starting parameters. To ensure a broad search 693 of parameter space, we initialized each curve fit multiple times (n=100) with starting 694 parameters randomly distributed between the bounds of each parameter. Fitted growth 695 rates often collapsed to the maximum µ tolerated; we therefore only retained fits where 696 growth rates were at least slightly below our upper bound for µ (µ < 2.5) (Supplementary 697 Fig. 13 ). Of the remaining fitted curves, we analyzed the one with the lowest loss 698 function. In our analyses of SV growth in human fecal samples, we defined total SV 699 levels as y(127 hours) -y(0 hours). 700
701
Microbiota dynamics in an artificial human gut 702
